Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

Core Insights - Nuvectis Pharma, Inc. announced a new publication demonstrating that the combination of NXP900 and osimertinib is superior to osimertinib alone in treating EGFR-mutated non-small cell lung cancer (NSCLC) [1] - The study showed decreased cell proliferation and increased apoptosis in vitro, supporting the rationale for combining NXP900 with EGFR inhibitors [1] - Nuvectis is progressing towards the initiation of the Phase 1b program for NXP900, with a Phase 1a dose escalation study nearing completion [2] Company Overview - Nuvectis Pharma is focused on developing innovative precision medicines for serious unmet medical needs in oncology, currently working on two clinical-stage drug candidates: NXP800 and NXP900 [3] - NXP800 is in a Phase 1b clinical trial for platinum-resistant, ARID1a-mutated ovarian carcinoma, while NXP900 is an oral small molecule inhibitor of SRC Family Kinases, currently in a Phase 1a dose escalation study [3]